Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
Rhea-AI Summary
Phathom Pharmaceuticals (Nasdaq: PHAT) will present at the Guggenheim Emerging Outlook Biotech Summit 2026. A management team fireside chat is scheduled for Thursday, February 12, 2026 at 11:30 am ET, with one-on-one meetings during the February 11-12 conference in New York.
Investors can access a live webcast and archived recording via the company website; recordings will remain available for 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PHAT declined 6.20%, reflecting a notable negative market reaction. This price movement removed approximately $64M from the company's valuation, bringing the market cap to $967M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PHAT was down 4.2% with several biotech peers also lower (IMNM, PRAX, EYPT, QURE) and URGN higher, indicating mixed but generally weak sentiment rather than a confirmed sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 07 | Public offering priced | Neutral | +10.4% | Pricing of common stock and pre-funded warrants raising about $130M gross. |
| Jan 07 | Offering announced | Neutral | +10.4% | Announcement of proposed public offering from an effective shelf registration. |
| Jan 07 | Prelim 2025 results | Positive | +10.4% | Preliminary 2025 revenues, operating expenses and cash usage plus VOQUEZNA milestones. |
| Nov 04 | Phase 2 trial start | Positive | -1.8% | First patient dosed in Phase 2 VOQUEZNA EoE study across ~80 adults at ~40 sites. |
| Nov 03 | Investor conferences | Neutral | +1.3% | Participation in multiple late‑2025 healthcare investor conferences with webcasts. |
Recent news has included financings, preliminary results, clinical progress, and conferences, with mostly positive or modest price reactions.
Over the last six months, PHAT has reported preliminary Q4/full-year 2025 financials, launched and priced a public equity offering with pre-funded warrants, and progressed VOQUEZNA into a Phase 2 EoE trial. It also regularly participates in investor conferences, including multiple events in Nov–Dec 2025. The current Guggenheim summit appearance continues this pattern of active investor outreach following capital raises and pipeline updates.
Regulatory & Risk Context
An automatic shelf registration on Form S-3ASR filed on Jan 07, 2026 allows PHAT to offer various securities from time to time, with specific terms defined in prospectus supplements. The shelf is effective and has been used in at least 2 offerings, as reflected in recent 424B5 filings.
Market Pulse Summary
The stock moved -6.2% in the session following this news. A negative reaction despite a routine conference announcement fits a market that has already digested substantial information from PHAT’s recent financings and preliminary 2025 results on Jan 07, 2026. The company’s active S-3ASR shelf and recent 424B5 usage highlight ongoing capital-raising flexibility, which some investors may view cautiously. Past news reactions have been mixed, so further downside or stabilization often depended on subsequent operational or regulatory updates.
AI-generated analysis. Not financial advice.
FLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team will participate in a fireside chat at the Guggenheim Emerging Outlook Biotech Summit 2026 on Thursday, February 12, 2026, at 11:30 am EST.
Company management will also participate in one-on-one meetings during the conference, which will run from February 11-12, 2026, in New York, NY.
To access the live webcast and archived recordings of the event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the meeting.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
FAQ
When is Phathom Pharmaceuticals (PHAT) presenting at the Guggenheim Emerging Outlook Biotech Summit 2026?
How can investors watch Phathom Pharmaceuticals (PHAT) live at the Guggenheim summit?
Will the Phathom Pharmaceuticals (PHAT) presentation recording be available after the Guggenheim summit?
What topics will Phathom Pharmaceuticals (PHAT) management cover at the Guggenheim Emerging Outlook Biotech Summit?
Where can I find the webcast and archived materials for Phathom Pharmaceuticals (PHAT) after the Guggenheim summit?
